Therapeutic Targeting of PKM2 Ameliorates NASH Fibrosis Progression in a Macrophage-Specific and Liver-Specific Manner

Therapeutic Targeting of PKM2 Ameliorates NASH Fibrosis Progression in a Macrophage-Specific and Liver-Specific Manner

Nonalcoholic steatohepatitis (NASH) may soon become the leading cause of end-stage liver disease worldwide with limited treatment options. Liver fibrosis, which is driven by chronic inflammation and hepatic stellate cell (HSC) activation, critically determines morbidity and mortality in patients wit...

Full description

Bibliographic Details
Main Authors: Hengdong Qu, Di Zhang, Junli Liu, Jieping Deng, Ruoyan Xie, Keke Zhang, Hongmei Li, Ping Tao, Genshu Wang, Jian Sun, Oscar Junhong Luo, Chen Qu, Wencai Ye, Jian Hong
Format: Article
Language:English
Published: Elsevier 2024-10-01
Series:Engineering
Subjects:
Pyruvate kinase M2
Macrophages
Nonparenchymal cells
Heteroduplex oligonucleotide
Nonalcoholic steatohepatitis
Liver fibrosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2095809924002650

Internet

http://www.sciencedirect.com/science/article/pii/S2095809924002650

Similar Items